Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study [version 2; peer review: 2 approved]

• Published in: F1000 research Vol. 11; p. 1178
• Main Authors: Ruiz-Villaverde, Ricardo, Rodriguez-Fernandez-Freire, Lourdes, Armario-Hita, Jose C., Pérez-Gil, Amalia, Vasquez Chinchay, Fiorella, Galán-Gutiérrez, Manuel
• Format: Journal Article
• Language: English
• Published: London Faculty of 1000 Ltd 2022
• Subjects: Body mass index; Clinical medicine; Clinical trials; Cohort analysis; Comorbidity; Cytokines; Demography; Dermatology; FDA approval; Hospitals; Inflammatory diseases; Monoclonal antibodies; Observational studies; Patients; Performance evaluation; Pruritus; Psoriasis; Psoriatic arthritis; Quality of life; Subpopulations; Survival; Survival analysis; United States > US; Spain; Demographic characteristics; Effectiveness; Safety; Psoriasis; Survival; Guselkumab
• DOI: 10.12688/f1000research.122945.2
• ISSN: 2046-1402

Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19. Multiple randomized clinical trials have demonstrated its efficacy in psoriasis, but response differences among patient subpopulations have not been extensively reported. Furthermore, patients in real life are often non-eligible for clinical trials and their responses may differ from pivotal studies. Methods: This is a retrospective, observational study of real clinical practice of patients receiving guselkumab treatment in Spain. Patients treated with guselkumab were included between February 2019 to December 2021. This study evaluates the potential differential effect of baseline demographic and disease characteristics on therapeutic responses to guselkumab. We measured effectiveness and survival by the psoriasis area and severity index, the dermatology life quality index as well as Kaplan meier curves, respectively. Categorical and quantitative variables are reported with frequencies, and with mean and standard deviation, respectively. Differences between groups in psoriasis area and severity index and dermatology life quality index, were calculated using a mixed-effects analysis. Survival was calculated using Kaplan meier curves and log-rank tests. Results: A total of 87 patients were included. In this study, our objective was to evaluate the effectiveness, safety and survival of guselkumab attending to demographic characteristics. No differences in psoriasis area and severity index or dermatology life quality index baseline values or therapeutic responses were noted at 52 weeks of follow-up among all the subgroups analysed (age, sex, psoriasis duration, body mass index, and comorbidities). A difference in drug survival was only seen between gender groups. Conclusions: Our research has demonstrated the consistency of guselkumab effectiveness across patient subgroups. No baseline features affected the effectiveness or drug survival of guselkumab, except for lower drug survival in female patients.